Mumbai, India & Naples, Florida, USA, August 10, 2026
Lupin Limited has announced that it has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet. The approval allows Lupin to market the generic product in the United States and expands the company’s portfolio of pharmaceutical products for the treatment of hyperkalemia in adults. The FDA has determined Lupin’s product to be bioequivalent to Lokelma® for Oral Suspension, the reference listed drug marketed by AstraZeneca Pharmaceuticals LP.
FDA Approves Generic Hyperkalemia Treatment
The approved Sodium Zirconium Cyclosilicate for Oral Suspension is available in two strengths, 5 g/packet and 10 g/packet, providing oral treatment options for adults with hyperkalemia. Hyperkalemia is a condition characterized by elevated potassium levels in the blood and can require medical management because abnormal potassium levels may create significant health risks. Lupin’s approval was granted through the Abbreviated New Drug Application pathway, which is used for the approval of generic medicines that demonstrate equivalence to an FDA-approved reference product. In this case, Lupin’s sodium zirconium cyclosilicate product has been approved as bioequivalent to Lokelma®, supporting its use for the same approved indication of treating hyperkalemia in adults.
The FDA approval represents an important regulatory milestone for Lupin as the company continues to expand its presence in the U.S. pharmaceutical market. The company’s portfolio includes generics, complex generics, specialty medicines, and biosimilars across multiple therapeutic areas.
Lupin Enters Significant U.S. Market Opportunity
Advertisement
According to the company, Sodium Zirconium Cyclosilicate for Oral Suspension, with Lokelma® as the reference listed drug, generated estimated annual U.S. sales of approximately $568 million, based on IQVIA MAT June 2026 data. The market opportunity provides Lupin with a significant commercial opportunity following the FDA approval.The availability of a generic version may also contribute to broader access to sodium zirconium cyclosilicate therapy in the United States.
Lupin’s two approved packet strengths provide flexibility within the product category while allowing the company to compete in an established pharmaceutical market. The FDA approval further demonstrates Lupin’s focus on developing and commercializing generic and complex pharmaceutical products for major global markets. The company maintains a broad presence across the United States, India, other developed markets, and emerging markets, with products distributed across more than 100 markets.
Lupin Strengthens Global Pharmaceutical Portfolio
Headquartered in Mumbai, India, Lupin operates a diversified pharmaceutical business covering generics, complex generics, specialty medicines, and biosimilars. The company maintains significant commercial and manufacturing capabilities across several therapeutic areas, including cardiovascular, respiratory, diabetes, gastrointestinal, and women’s health. Lupin operates 15 manufacturing facilities and six research centers, supported by a global workforce of more than 26,000 professionals. The company is also expanding its broader healthcare activities through diagnostics, digital health, patient-support programs, and disease-management initiatives.
The approval of sodium zirconium cyclosilicate adds another FDA-approved product to Lupin’s U.S. portfolio and highlights the company’s continued efforts to expand its presence in high-value pharmaceutical markets. With the product approved as bioequivalent to the reference listed drug and indicated for adult hyperkalemia, the milestone represents progress in Lupin’s generic drug development and commercialization strategy. The FDA decision reinforces Lupin’s focus on bringing affordable pharmaceutical alternatives to patients while expanding its portfolio of products across important therapeutic categories. The company can now leverage its established U.S. commercial presence to support the launch and availability of sodium zirconium cyclosilicate oral suspension.
Source: Lupin press release
